艾力斯：创新药伏美替尼、戈来雷塞纳入新版国家医保目录

Core Viewpoint - The company艾力斯(688578.SH) announced that its innovative drugs, Fumetinib (trade name "艾弗沙") and Golecitinib (trade name "艾瑞凯"), have been included in the National Medical Insurance Directory for 2025, which is a significant development for the company's market access and potential revenue growth [1] Group 1 - Fumetinib has been retained in the National Medical Insurance Directory for first-line and second-line treatment indications after successful negotiations [1] - Golecitinib has been included in the National Medical Insurance Directory for second-line treatment indications for the first time through negotiation [1]